Filing Analysis
Elicio Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026, and provided various corporate updates via a press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026.
- Announcement date: August 13, 2026.
- The filing includes financial results and corporate updates furnished in Exhibit 99.1.
Elicio Therapeutics, Inc. entered into a Securities Purchase Agreement to conduct a registered direct offering of 4,380,313 shares at $3.43 per share. The offering aims to raise approximately $15 million in gross proceeds from institutional investors.
🚩 Red Flags
- Dilution risk for existing shareholders due to the issuance of over 4 million new shares.
- The company is an 'emerging growth company,' which often correlates with higher cash burn and reliance on external financing.
📋 Key Facts
- Offering size: 4,380,313 shares of common stock.
- Offering price: $3.43 per share.
- Gross proceeds: Approximately $15 million (before fees and expenses).
- Expected closing date: July 6, 2026.
- Placement agents: Titan Partners Group, LLC (Lead) and B. Riley Securities, Inc. (Co-agent).
- Registration method: Registered direct offering via Form S-3.
Elicio Therapeutics hosted a virtual key opinion leader (KOL) event to discuss the clinical development path for ELI-002 7P in treating metastatic KRAS-driven pancreatic cancer. The presentation featured prominent medical experts from UCLA and the University of Miami.
📋 Key Facts
- Event Date: June 24, 2026
- Focus Product: ELI-002 7P
- Target Indication: Metastatic mutant KRAS-driven pancreatic ductal adenocarcinoma
- Featured Speakers: Dr. Zev Wainberg (UCLA) and Dr. Peter Hosein (University of Miami)
- The information was furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes.
Elicio Therapeutics announced preliminary clinical observations for ELI-002 7P and expressed intent to conduct a Phase 1 study for first-line metastatic mutant KRAS pancreatic ductal adenocarcinoma.
🚩 Red Flags
- The planned Phase 1 study is contingent upon securing funding, indicating potential capital constraints.
📋 Key Facts
- Company announced preliminary clinical observations supporting the use of ELI-002 7P in combination with checkpoint inhibition.
- Plans were announced for a Phase 1 study in first-line metastatic mutant KRAS pancreatic ductal adenocarcinoma.
- The commencement of the Phase 1 study is explicitly stated as being 'subject to funding'.
Elicio Therapeutics announced the results of its randomized Phase 2 AMPLIFY-7P study for the treatment of adjuvant mutant KRAS-driven pancreatic ductal adenocarcinoma and provided a refined Phase 3 development strategy for ELI-002 7P.
📋 Key Facts
- The company released results from the Phase 2 AMPLIFY-7P study on June 15, 2026.
- The study focuses on adjuvant mutant KRAS-driven pancreatic ductal adenocarcinoma.
- The company has outlined a refined Phase 3 development strategy for its candidate ELI-002 7P.
Elicio Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026, and provided general corporate updates. The information was furnished via a press release attached as Exhibit 99.1.
📋 Key Facts
- Financial results cover the quarter ended March 31, 2026.
- The report was filed on May 11, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The company maintains its status as an emerging growth company.
- The filing was signed by Robert Connelly, President and Chief Executive Officer.
Elicio Therapeutics has established a new $100 million at-the-market (ATM) equity offering program and terminated its existing $40 million ATM facility.
🚩 Red Flags
- Potential for significant shareholder dilution totaling up to $100 million
- Substantial increase in the size of the ATM facility from $40 million to $100 million may indicate high future capital requirements
📋 Key Facts
- Entered into an At Market Issuance Sales Agreement for up to $100.0 million in common stock on March 16, 2026
- Agents for the new offering are B. Riley Securities, JonesTrading, and Ladenburg Thalmann
- The company will pay a 3.0% commission on gross sales proceeds
- Terminated a prior $40.0 million Sales Agreement with JonesTrading originally entered into on June 3, 2024
- The offering is conducted via a registration statement on Form S-3 (File No. 333-293861)
Elicio Therapeutics announced its financial results for the full year ended December 31, 2025, and provided corporate updates via a press release on March 12, 2026.
📋 Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The announcement was made on March 12, 2026, via a press release furnished as Exhibit 99.1.
- The report includes corporate updates alongside the financial data.
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Elicio Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025 and provided general corporate updates via a press release.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes the announcement of financial results and corporate updates under Item 2.02.
- Company is classified as an emerging growth company.
Elicio Therapeutics announced positive immunogenicity data from its ongoing Phase 2 AMPLIFY-7P trial for ELI-002 7P. The data shows robust mKRAS-specific T cell responses in 99% of evaluable patients, demonstrating consistency with previous Phase 1 clinical results.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- ELI-002 7P achieved mKRAS-specific T cell responses in 99% (89 of 90) of evaluable patients in the Phase 2 AMPLIFY-7P trial.
- Observed average increase in T cell response was 145.3x over baseline, significantly higher than the 71.1x seen in Phase 1.
- The median fold change in Phase 2 was 44.3x, compared to 18.5x in Phase 1.
- CD4 and CD8 T cell response rate was 85%, up from 75% in the previous Phase 1 trial.
- 67.4% of patients exhibited responses for all seven mKRAS antigens, compared to 50% in Phase 1.
- Data cutoff for the Phase 2 trial results is August 22, 2025.
Elicio Therapeutics announced the publication of follow-up data from its Phase 1 AMPLIFY-201 study evaluating ELI-002 in the scientific journal Nature Medicine. The filing serves to incorporate a press release containing these clinical results into the company's official SEC record.
📋 Key Facts
- Publication of Phase 1 AMPLIFY-201 follow-up data for ELI-002.
- Data published in the peer-reviewed journal Nature Medicine.
- Report date: August 12, 2025.
Elicio Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025, and provided various corporate updates via a press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025
- Announcement date: August 7, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an 'Emerging Growth Company'
Elicio Therapeutics announced that an Independent Data Monitoring Committee (IDMC) reviewed interim safety and efficacy data for its Phase 2 AMPLIFY-7P study in pancreatic cancer. The IDMC recommended the trial proceed to final analysis without any modifications.
📋 Key Facts
- Interim review of unblinded safety and efficacy data completed for Phase 2 AMPLIFY-7P study.
- Target indication: mutant KRAS-driven pancreatic ductal adenocarcinoma.
- IDMC recommendation: continue trial to final analysis without modifications.
- The announcement was made on August 5, 2025.
Elicio Therapeutics entered into a $10.0 million senior secured promissory note agreement with GKCC, LLC, an entity controlled by a member of the company's board of directors. The financing includes a warrant to purchase 103,225 shares and is secured by first-priority liens on substantially all assets and intellectual property.
🚩 Red Flags
- Related-party transaction: The lender is controlled by a company director.
- High-security collateral: The note is secured by first-priority liens on all assets and IP.
- Restrictive covenants: Includes negative covenants restricting the ability to incur debt, make dividends, or consummate affiliate transactions.
- Punitive default terms: Interest rate jumps to 18% upon acceleration.
📋 Key Facts
- Date of agreement: June 3, 2025
- Principal amount: $10.0 million Senior Secured Promissory Note
- Maturity date: June 3, 2028
- Interest rate: Prime Rate + 5.00% (capped at 12.5% per annum)
- Default interest rate: 18% per annum upon acceleration
- Collateral: First priority lien on substantially all assets and intellectual property
- Warrant: 103,225 shares of common stock at an exercise price of $7.75 per share
- Purchaser: GKCC, LLC (controlled by a board member)
Elicio Therapeutics, Inc. held its 2025 annual meeting of stockholders on May 19, 2025. The company successfully passed all proposals, including the election of two directors and the ratification of Baker Tilly US, LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on May 19, 2025.
- Quorum established with 11,172,771 shares (70.1% of voting power) represented.
- Karen J. Wilson elected to the Board of Directors until the 2028 annual meeting.
- Robert R. Ruffolo, Jr., Ph.D., FCPP elected to the Board of Directors until the 2028 annual meeting.
- Baker Tilly US, LLP ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
Elicio Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2025, and provided various corporate updates via a press release.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Filing date: May 13, 2025
- The filing includes results of operations and financial condition (Item 2.02)
- Company is an emerging growth company
Elicio Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2024, and provided general corporate updates via a press release.
📋 Key Facts
- Report date: March 31, 2025
- Reporting period: Year ended December 31, 2024
- The filing includes results of operations and financial condition under Item 2.02.
- Company is an emerging growth company.
Elicio Therapeutics, Inc. has appointed Preetam Shah, Ph.D., M.B.A. as the new Chief Strategy and Financial Officer, effective March 24, 2025. Dr. Shah will also assume the roles of Principal Financial Officer and Principal Accounting Officer on April 1, 2025.
📋 Key Facts
- Appointment of Preetam Shah as Chief Strategy and Financial Officer effective March 24, 2025.
- Dr. Shah to serve as Principal Financial Officer and Principal Accounting Officer starting April 1, 2025.
- Annual base salary set at $480,000 with a target performance bonus of 40% of base salary.
- Initial option grant equal to 1.2% of total common stock outstanding as of April 15, 2025, vesting over four years (25% after one year, then monthly).
- Dr. Shah brings significant biotech experience from Cidara Therapeutics and Brainstorm Cell Therapeutics.
Elicio Therapeutics exercised its right to force the conversion of a $20 million Senior Secured Convertible Promissory Note into common stock. The transaction involved an entity controlled by a member of the Company's Board of Directors.
🚩 Red Flags
- Related-party transaction: The note holder is controlled by a Board member.
- Significant dilution: Issuance of over 3.5 million shares into a float of approximately 15.8 million shares represents substantial ownership concentration/dilution for existing shareholders.
- Convertible debt structure often used in micro-cap financing can lead to 'death spiral' dynamics if not carefully managed.
📋 Key Facts
- The Company exercised its right on March 3, 2025, to require conversion of the full principal and accrued interest.
- Total shares issued: 3,500,573 shares of Common Stock.
- Purchaser is GKCC, LLC, an entity controlled by a member of the Company's Board of Directors.
- The Convertible Note was originally entered into on August 12, 2024, with a principal amount of $20.0 million.
- Post-issuance total shares outstanding: 15,861,913 shares.
- Conversion triggered by the stock price meeting a threshold (135% of the initial conversion price of $5.81) for 20 out of 30 trading days.
Elicio Therapeutics announced a registered direct offering of common stock and warrants to institutional investors for approximately $10 million in gross proceeds. The offering is priced at $7.925 per unit.
🚩 Red Flags
- Dilutive offering: Issuance of significant new shares and warrants will dilute existing shareholders.
- Warrant overhang: The issuance of nearly equal number of warrants to the common stock creates potential future dilution at $7.80 per share.
📋 Key Facts
- Aggregate gross proceeds: Approximately $10 million (before fees).
- Securities offered: 1,261,830 shares of common stock and 1,261,830 warrants to purchase common stock.
- Combined offering price: $7.925 per share and warrant unit.
- Warrant terms: Exercise price of $7.80 per share; immediately exercisable; expires in five years.
- Placement Agent: H.C. Wainwright & Co., LLC (7.0% cash fee plus expenses).
- Closing date: Expected January 30, 2025.
Elicio Therapeutics, Inc. has filed an 8-K to furnish a corporate presentation updated as of January 23, 2025. This is a routine regulatory filing used to provide supplemental information to the public via the company's website.
📋 Key Facts
- The filing was made on January 23, 2025.
- The company uploaded an updated corporate presentation (Exhibit 99.1) to its website.
- The presentation is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Elicio Therapeutics announced that it received supportive feedback from the FDA during an End of Phase 1 Type B meeting regarding its Phase 3 registrational strategy for ELI-002.
📋 Key Facts
- Meeting type: End of Phase 1 Type B meeting with the U.S. FDA.
- Subject matter: Phase 3 registrational strategy for product candidate ELI-002.
- Outcome: The Company received 'supportive feedback' from the regulator.
Elicio Therapeutics issued an 8-K to provide a corporate presentation and announce updated clinical results from its ELI-002 Phase 1 AMPLIFY-201 study presented at the ESMO Immuno-Oncology Congress.
📋 Key Facts
- Company uploaded a new corporate presentation (Exhibit 99.1) on December 12, 2024.
- Announced updated results from ELI-002 Phase 1 AMPLIFY-201 study.
- Clinical data was presented at the ESMO Immuno-Oncology Congress 2024 in Geneva, Switzerland (Dec 11-13, 2024).
- The filing includes a press release as Exhibit 99.2.
Elicio Therapeutics announced the successful completion of patient enrollment for its ELI-002 Phase 2 AMPLIFY-7P clinical study. This is a routine operational update regarding clinical trial progress.
📋 Key Facts
- Completion of enrollment in the ELI-002 Phase 2 AMPLIFY-7P study was announced on December 3, 2024.
- The announcement was made via press release (Exhibit 99.1).
- Company is an emerging growth company.
Elicio Therapeutics, Inc. held its 2024 annual meeting of stockholders on November 21, 2024. Stockholders approved the election of three directors, the ratification of Baker Tilly US, LLP as independent auditors, and a Nasdaq-required approval for share issuances related to warrants and convertible notes.
🚩 Red Flags
- Proposal 3 involves the conversion of 'certain convertible notes,' which can lead to significant dilution for existing shareholders.
📋 Key Facts
- Annual Meeting held on November 21, 2024.
- Quorum reached with 7,452,994 shares voted (69.17% of voting power).
- Three directors elected: Robert Connelly, Yekaterina Chudnovsky, and Allen R. Nissenson, M.D.
- Baker Tilly US, LLP ratified as independent registered public accounting firm for FY 2024.
- Stockholders approved the issuance of common stock upon exercise of warrants and conversion of a convertible note per Nasdaq Listing Rule 5635(b).
- All three proposals passed.
Elicio Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024 and provided corporate updates via a press release.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes results of operations and financial condition under Item 2.02
- Company is an emerging growth company
Elicio Therapeutics issued an 8-K to announce the presentation of updated translational data from its ELI-002 Phase 1 AMPLIFY-7P study. The data, which includes T cell and disease-free survival updates, was presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting.
📋 Key Facts
- Presentation of updated translational data from ELI-002 Phase 1 AMPLIFY-7P study.
- Data includes updated T cell and disease-free survival metrics.
- Presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas.
- Filing date: November 7, 2024.
Elicio Therapeutics, Inc. adjourned its virtual annual meeting of stockholders on November 7, 2024, due to the lack of a quorum. The meeting is scheduled to reconvene virtually on November 21, 2024.
🚩 Red Flags
- Lack of quorum at the annual meeting suggests low shareholder engagement or potential apathy/disengagement from the investor base.
📋 Key Facts
- The Annual Meeting held on Nov 7, 2024, was adjourned because a quorum was not present in person or by proxy.
- A majority of the shares represented by proxies received at adjournment had voted in favor of each proposal.
- The meeting will reconvene virtually on Thursday, November 21, 2024, at 9:30 a.m. ET.
- Preregistration for the reconvened meeting must be completed by Nov 20, 2024, at 11:59 p.m. ET.
- The record date remains September 11, 2024.
Elicio Therapeutics, Inc. announced the appointment of Robert Connelly as Principal Accounting Officer (PAO) and Principal Financial Officer (PFO), effective October 15, 2024.
🚩 Red Flags
- Dual role: The CEO is also assuming the Principal Financial Officer (PFO) and Principal Accounting Officer (PAO) roles, which can indicate a lack of specialized financial leadership or resource constraints common in micro-cap biotech firms.
📋 Key Facts
- Robert Connelly appointed as Principal Accounting Officer and Principal Financial Officer on October 15, 2024.
- Mr. Connelly is the current CEO and President of Elicio Therapeutics, Inc.
- Connelly has nearly 40 years of experience in life sciences leadership roles.
- Previous leadership roles include CEO at Axcella Health Inc., WikiCell Designs, Pulmatrix, Inc., and Domantis Ltd.
Elicio Therapeutics, Inc. announced the resignation of its Chief Financial Officer (CFO) and Treasurer, Brian Piekos, effective September 6, 2024. The departure is reportedly for personal reasons to pursue another opportunity and not due to any disagreements regarding financial reporting.
🚩 Red Flags
- Unexpected leadership turnover in a key finance role (CFO) can sometimes precede internal scrutiny, though no disagreement was cited here.
📋 Key Facts
- Brian Piekos is resigning from his roles as CFO and Treasurer.
- The resignation is effective September 6, 2024.
- The company stated the departure is not related to any disagreement over financial reporting or accounting policies.
- The company has initiated a search for a replacement CFO.
Elicio Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2024, and provided various corporate updates via a press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Announcement date: August 13, 2024
- The filing includes results of operations and financial condition (Item 2.02).
- Company is classified as an emerging growth company.
Elicio Therapeutics entered into a $20.0 million senior secured convertible promissory note agreement with GKCC, LLC to fund working capital. The financing is notable due to its high-security nature and the fact that the purchaser is an entity controlled by a board member.
🚩 Red Flags
- Related-party transaction: The purchaser is controlled by a board member.
- High-security collateral: The note is secured by first priority liens on all assets and IP.
- Potential for significant dilution via convertible equity.
- Default penalty: Interest rate jumps to 18% per annum upon an Event of Default.
📋 Key Facts
- Issued 3.0% Senior Secured Convertible Promissory Note due February 15, 2026.
- Principal amount: $20.0 million; estimated net proceeds: $19.7 million.
- Purchaser (GKCC, LLC) is controlled by a member of the Company's Board of Directors.
- The Note is secured by a first priority lien on substantially all assets and intellectual property of the Company.
- Initial conversion price set at $5.81 per share, subject to stockholder approval.
- Includes a 'forced conversion' trigger if the stock trades at 135% of the conversion price for 20 out of 30 trading days.
Elicio Therapeutics, Inc. entered into an underwriting agreement on June 28, 2024, to conduct an underwritten offering of common stock and warrants. The offering aims to raise approximately $10.9 million in net proceeds to fund the company's development pipeline and working capital.
🚩 Red Flags
- Significant potential dilution due to the issuance of up to 2.3 million common warrants and 1.8 million pre-funded warrants.
- The use of proceeds includes 'working capital,' which often indicates a need for immediate cash to sustain operations.
📋 Key Facts
- Offering includes 500,000 shares of Common Stock and 1,800,000 pre-funded warrants at a combined price of $5.00 per share/warrant unit.
- Common Warrants to purchase up to 2,300,000 additional shares are included with an exercise price of $5.00 per share.
- Net proceeds expected to be approximately $10.9 million after expenses and commissions.
- The offering was conducted via a shelf registration statement (Form S-3) declared effective on June 11, 2024.
- Common Warrants and Pre-Funded Warrants will not be listed on Nasdaq.
Elicio Therapeutics announced preliminary disease-free survival (DFS) data from its Phase 1a AMPLIFY-7P study evaluating ELI-002 7P for mKRAS-driven solid tumors. The data shows promising trends in patients receiving the higher dose level, though median DFS has not yet been reached for the high-dose cohort.
🚩 Red Flags
- Clinical stage company: Results are preliminary and based on a small sample size (n=14 total).
📋 Key Facts
- Announced preliminary disease-free survival (DFS) analysis from AMPLIFY-7P Phase 1a study as of May 24, 2024 data cutoff.
- The study evaluates ELI-002 7P in patients with mKRAS-driven solid tumors using two dose levels: 1.4 mg and 4.9 mg AMP-peptide.
- In the 4.9 mg dose group (n=8), median DFS has not been reached, compared to 12.6 weeks for the 1.4 mg dose group (n=6).
- Median follow-up for the DFS endpoint was 29.1 weeks.
- Patients with an above-median T cell response have had no progression events as of the data cutoff date.
- Patients achieving a reduction in tumor biomarker levels showed no progression events.
Elicio Therapeutics announced the presentation of preliminary data from its Phase 1 AMPLIFY-7P study for ELI-002 7P at the upcoming ASCO Annual Meeting. The data pertains to patients with mKRAS-driven solid tumors.
📋 Key Facts
- Company is presenting preliminary data from the ongoing AMPLIFY-7P Phase 1 study.
- The therapeutic candidate is ELI-002 7P, a cancer vaccine for mKRAS-driven solid tumors.
- Presentation scheduled for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024).
- The filing is an Item 8.01 'Other Events' disclosure.
Elicio Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024 and provide general corporate updates.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Filing date: May 15, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Company is an emerging growth company.
Elicio Therapeutics announced the presentation of updated clinical and preclinical data at the American Association for Cancer Research (AACR) Annual Meeting. The update includes Phase 1 study data for ELI-002 and preclinical data for ELI-007 and ELI-008.
📋 Key Facts
- Presentation of updated clinical T cell and antigen spreading response data from the Phase 1 (AMPLIFY-201) study of ELI-002.
- Presentation of preclinical data on ELI-007 and ELI-008.
- Data presented at the American Association for Cancer Research Annual Meeting (April 5-10, 2024).
- The company is an emerging growth company.
Elicio Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023, and provided various corporate updates via a press release.
📋 Key Facts
- Report date: March 29, 2024
- Reporting period: Year ended December 31, 2023
- The filing includes an announcement of financial results and corporate updates (Exhibit 99.1).
- Company is classified as an 'emerging growth company'.
Elicio Therapeutics entered into a $6.0 million subscription agreement with GKCC, LLC, an entity controlled by a member of the company's board of directors, for the issuance of pre-funded warrants. The transaction involves significant potential dilution and includes specific registration obligations and Nasdaq compliance requirements regarding beneficial ownership.
🚩 Red Flags
- Related-party transaction: The purchaser is controlled by a board member.
- Significant dilution risk due to the issuance of over 1 million pre-funded warrants at a nominal $0.01 exercise price.
- Potential Nasdaq compliance issue regarding beneficial ownership (Section 5635(b)) if shares are exercised.
📋 Key Facts
- The offering is for up to 1,032,702 pre-funded warrants at a price of $5.81 per warrant.
- Gross proceeds are expected to be approximately $6.0 million.
- The purchaser (GKCC, LLC) is controlled by a member of the company's Board of Directors.
- Warrants are exercisable at $0.01 per share.
- The company must file an SEC registration statement for the shares by June 30, 2024.
- A potential change of control/ownership issue exists if beneficial ownership exceeds 19.99% upon exercise.
Elicio Therapeutics announced compensation adjustments for its CEO and CSO, including base salary increases and new stock option grants. Additionally, the Board adopted a new Executive Severance Plan for key officers.
🚩 Red Flags
- Adoption of an Executive Severance Plan (potential liquidity drain during change in control events).
📋 Key Facts
- CEO Robert Connelly's base salary increased to $608,400 with a 55% performance bonus opportunity, effective Jan 1, 2024.
- CSO Pete DeMuth's base salary increased to $460,000 with a 40% performance bonus opportunity, effective Jan 1, 2024.
- New stock option grants issued Feb 1, 2024: 225,137 shares for CEO and 29,800 shares for CSO.
- The Board adopted an Executive Severance Plan covering the CEO and other executive officers.
- Severance includes salary continuation/lump sum, COBRA coverage, and accelerated vesting of equity in certain termination scenarios.
Elicio Therapeutics announced a poster presentation at the ASCO Gastrointestinal Cancers Symposium regarding their Phase 1/2 (AMPLIFY-7P) study design for ELI-002 7P, an investigational cancer vaccine.
📋 Key Facts
- The company is presenting a 'Trial in Progress' poster at the ASCO GI Symposium (Jan 18-20, 2024).
- The presentation focuses on the AMPLIFY-7P study design.
- ELI-002 7P is an investigational therapeutic cancer vaccine for adjuvant monotherapy treatment.
- Target patient population: KRAS-mutated pancreatic ductal adenocarcinoma (PDAC).
Elicio Therapeutics provided an update on its existing At-The-Market (ATM) equity offering program. The company reported net proceeds of approximately $4.89 million from the sale of 584,170 shares since the quarter ended September 30, 2023.
🚩 Red Flags
- Continued reliance on ATM offerings suggests a need for ongoing cash infusion to fund operations.
📋 Key Facts
- ATM Agreement originally entered into on May 16, 2022, with Stifel and Virtu Americas LLC.
- Aggregate offering size is up to $21.0 million.
- 584,170 shares have been sold since the end of Q3 2023 (Sept 30, 2023).
- Net sale proceeds from these recent sales totaled approximately $4.89 million.
Elicio Therapeutics announced the publication of updated preliminary Phase 1 data for its lead asset, ELI-002, in Nature Medicine. The company also released an updated corporate presentation.
📋 Key Facts
- Publication of updated preliminary data from Phase 1 (AMPLIFY-201) solid tumor study.
- Lead asset identified as ELI-002.
- Data published in the journal Nature Medicine.
- Updated corporate presentation released on January 9, 2024.